Meeting
2023 ASCO Annual Meeting
Mutation-site localized non-B DNA burden and survival heterogeneity in early-stage pancreatic cancer.
Authors
Qi Xu
Livestrong Cancer Institutes, University of Texas at Austin, Austin, TX
Qi Xu , Jeanne Kowalski-Muegge
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer - Local-Regional Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4166)
DOI
10.1200/JCO.2023.41.16_suppl.4166
Abstract #
4166
Poster Bd #
487
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase II study of the MEK inhibitor refametinib (BAY 86-9766) in combination with gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer: Biomarker results.
First Author: Hanno Riess
Poster
2023 ASCO Gastrointestinal Cancers Symposium
The Endoscopic Ultrasound Molecular Analysis of Pancreatic Cancer (EUMEPC) study.
First Author: Joanne Lundy
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Comprehensive characterization of mesothelin expression in colorectal cancer.
First Author: Midhun Malla
Poster
2022 ASCO Annual Meeting
Evaluation of stage IV pancreatic adenocarcinomas based on mutational profiling of tumors.
First Author: Katherine E Poruk